clobetasol and Alopecia

Congenital triangular alopecia (CTA) is a developmental anomaly characterized by a bald patch involving the temporal region on one or, more rarely, both sides. We report 5 patients with CTA showing a central island of short hair that was categorized as terminal hair both macroscopically and microscopically. The cause of this paradoxical phenomenon is unknown.

Topics: Adolescent; Adult; Alopecia; Child; Clobetasol; Female; Genetic Diseases, X-Linked; Hair; Humans; Male; Molluscum Contagiosum; Treatment Outcome; Triamcinolone Acetonide

Lichen planopilaris (LPP) is a scarring alopecia for which no treatment with remarkable effect has been identified. Pioglitazone has been reported as a possible therapeutic option. To compare the efficacy and safety of pioglitazone with clobetasol in LPP. This randomized, double-blind, parallel-group was conducted at Razi hospital. Patients were treated either with pioglitazone 15 mg/daily or clobetasol lotion 0.05% once at night for 6 months. Patients were visited every 2 months to assess the lichen planopilaris activity index (LPPAI) and record probable adverse events. Forty patients (mean age: 43.6 years; 62.5% female) were randomized 1:1. The mean of LPPAI at baseline and last session were 4.68 ± 1.97 and 2.59 ± 0.97 in the clobetasol group and 5.01 ± 1.71 and 3.04 ± 1.36 in the pioglitazone group, respectively. Both treatments significantly decreased the LPPAI over the two-month interval visits (p < 0.001). No significant difference in the LPPAI reduction was detected between groups. Regarding the safety profile, three clobetasol-treated patients developed folliculitis, and two in the pioglitazone group developed mild headaches. Pioglitazone effectively controlled the signs and symptoms of the LPP with no serious side effects. It can be considered a treatment option for LPP, although it was not superior to clobetasol.

Topics: Adult; Alopecia; Clobetasol; Female; Humans; Lichen Planus; Male; Pioglitazone; Treatment Outcome

Frontal fibrosing alopecia (FFA) is a scarring alopecia with no promising treatment.. To evaluate the additive efficacy of oral isotretinoin to topical treatments.. Between November 2017 and August 2018, FFA patients were randomly assigned to receive either isotretinoin (20 mg/d) plus topical treatments (clobetasol 0.05% and tacrolimus 0.1%) or monotherapy with topical treatments. Treatments' efficacy was evaluated through Frontal Fibrosing Alopecia Severity Index (FFASI) after two and 6 months.. From 38 participants, 28 patients completed the study. Facial papules improved after 6 months (. Small sample size and lost to follow-up.. Isotretinoin combined with topical treatments is more effective than monotherapy with clobetasol and tacrolimus for FFA.. (IRCT.ir) IRCT2017091736173N1.

Topics: Alopecia; Clobetasol; Forehead; Humans; Isotretinoin; Tacrolimus

Lichen planopilaris (LPP) is one of the important causes of cicatricial alopecia. We aimed to evaluate the efficacy and safety of low-dose naltrexone (LDN) in the setting of a clinical trial in patients with LPP.. We included patients with LPP between 2018 and 2020. Patients were allocated to two groups. The first group received topical clobetasol plus oral low dose naltrexone (3 mg) while the second received topical clobetasol plus placebo. The assessment was made for the disease severity by lichen planopilaris activity index (LPPAI) instrument and the safety of the drug in 2-month intervals up to 6 months. To compare both groups, we used the ANOVA test for repeated measures. Clinical trials registry code: IRCT20180809040747N1.. Thirty-four patients were analyzed in an intention-to-treat fashion. There was a decrescendo pattern on LPPAI scores that was statistically significant within the LDN (. Low-dose naltrexone (3 mg) failed to improve the severity of the LPP more than what is achievable with topical clobetasol.

Topics: Alopecia; Cicatrix; Clobetasol; Humans; Lichen Planus; Naltrexone

Background: There is currently an unmet need for the treatment of women with central centrifugal cicatricial alopecia (CCCA). Objective: To evaluate the safety and efficacy of Clobetasol propionate 0.05% emollient foam for the treatment of women with CCCA. Methods: Adult women of African descent that presented with clinical evidence of early CCCA were enrolled (N=30). Clobetasol propionate 0.05% emollient foam was applied daily in an open-label fashion. Safety and efficacy assessments were performed at weeks 2, 6, 12, and 14. Results: Subjects achieved substantial improvements in pruritus, pain, tenderness, erythema and scaling. Scalp biopsies revealed considerable improvements in severe inflammation and perifollicular edema. Overall, clobetasol propionate 0.05% emollient foam was well-tolerated. Limitations: This was a nonrandomized, open-label study. Enrollment was limited to subjects with clinically mild CCCA. Conclusion: Subjects with CCCA that applied topical clobetasol propionate 0.05% emollient foam to their scalp daily demonstrated continuous clinical improvement throughout the 14-week study. ClinicalTrials.gov Identifier: NCT01111981 J Drugs Dermatol. 2020;19(7): doi:10.36849/JDD.2020.5201.

Topics: Administration, Cutaneous; Adult; Aged; Alopecia; Anti-Inflammatory Agents; Clobetasol; Emollients; Female; Humans; Middle Aged; Severity of Illness Index; Treatment Outcome; Young Adult

Oral Janus kinase (JAK) inhibitors are currently being investigated in phase II and phase III clinical trials for several inflammatory skin diseases including alopecia areata (AA). Topical JAK inhibitors have been investigated in atopic dermatitis, psoriasis, and AA. While a number of case series using topical JAK inhibitors in AA have been published, to date there have been no randomized controlled clinical trials.. We conducted a phase I, 28 week prospective, placebo-controlled, double-blind study in patients with alopecia universalis investigating hair regrowth with two topical JAK inhibitors, 2% tofacitinib and 1% ruxolitinib. Topical clobetasol dipropionate 0.005% was the active comparator while vehicle was used as the placebo control. Sixteen patients were recruited for the study.. Six patients demonstrated partial hair regrowth in areas treated with 2% tofacitinib ointment applied twice daily. Five patients demonstrated partial hair regrowth in the areas treated with 1% ruxolitinib ointment. Ten patients demonstrated partial hair regrowth in the areas treated with clobetasol dipropionate 0.05% ointment. No regrowth was observed in the placebo treated area. Interestingly, generalized hair regrowth was observed in two patients. One patient had 100% regrowth over his entire scalp and eyebrows by week 24 but relapsed after 12 weeks. A second patient also experienced generalized scalp regrowth and significant eyebrow growth and continued to maintain growth 14 weeks later.. Our findings suggest that topical JAK inhibitors could be developed as a potential new treatment for AA and alternative to clobetasol dipropionate 0.05% ointment.

Topics: Administration, Cutaneous; Alopecia; Clobetasol; Double-Blind Method; Glucocorticoids; Hair; Humans; Janus Kinase Inhibitors; Nitriles; Ointments; Pilot Projects; Piperidines; Prospective Studies; Pyrazoles; Pyrimidines; Pyrroles

Lichen planopilaris (LPP) is a scarring alopecia rarely described in men.. To investigate the clinical and histopathologic features of LPP in men.. We performed a retrospective cohort study of male patients with LPP seen at Mayo Clinic between 1992 and 2016.. Nineteen men with biopsy-confirmed LPP were included. The disease most commonly presented with diffuse (42.1%) or vertex scalp (42.1%) involvement. None of the patients had eyebrow or body hair involvement. Perifollicular erythema (94.7%) and pruritus (57.9%) were the most frequent clinical findings. Androgenetic alopecia (AGA) co-occurred in 26.3% of patients. Mucosal lichen planus was found in four patients (21.1%). Thyroid disease occurred in three patients (15.8%). Disease improvement (47.3%) occurred with combination topical and systemic therapy, topical clobetasol monotherapy, and minocycline monotherapy.. LPP in men has similar clinical and histologic presentations as reported in women. Nonscalp hair loss appears less likely in men with classic LPP than reported in men with frontal fibrosing alopecia, while mucosal lichen planus and thyroid disease appear to be more common in classic LPP. Men with AGA can present with new-onset concomitant LPP. Limitations included small study size, variable follow-up, and lack of standardized clinical assessment due the study's retrospective nature.

Topics: Alopecia; Clobetasol; Female; Humans; Lichen Planus; Male; Retrospective Studies; Scalp

Topics: Alopecia; Antineoplastic Agents, Immunological; Clobetasol; Female; Glucocorticoids; Hair Color; Humans; Melanoma; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Skin Neoplasms; Treatment Outcome

Topics: Adult; Aged; Alopecia; Clobetasol; Dermoscopy; Disease Progression; Drug Therapy, Combination; Dutasteride; Female; Fibrosis; Follow-Up Studies; Hair Follicle; Humans; Inflammation; Middle Aged; Prospective Studies; Severity of Illness Index; Skin; Treatment Outcome; Triamcinolone

Topics: Alopecia; Bone Diseases, Metabolic; Clobetasol; Female; Glucocorticoids; Humans; Hydroxychloroquine; Lichen Planus; Middle Aged; Ossification, Heterotopic; Scalp; Scalp Dermatoses; Skin Diseases, Genetic; Treatment Outcome

Topics: Administration, Topical; Aged; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; B7-H1 Antigen; Clobetasol; Female; Glucocorticoids; Hair; Humans; Minoxidil; Treatment Outcome; Ultrasonography; Ureteral Neoplasms

Topics: Alopecia; Clobetasol; Eyebrows; Facial Dermatoses; Female; Glucocorticoids; Hair Follicle; Humans; Hydroxychloroquine; Middle Aged; Treatment Outcome

Primary cicatricial alopecia (PCA) is a dermatological challenge. Because no large-scale epidemiological study regarding PCA is available yet, we investigated the National Health Insurance Service-National Sample Cohort for patients diagnosed with PCA. The annual and overall rates of incidence and prevalence of PCA during the study period (2004-2013) were estimated. Distribution of PCA subtypes, disease co-occurrence rates and frequently prescribed medications were also evaluated. The overall incidence was 6.10 (95% confidence interval [CI], 5.62-6.60) per 100 000 person-years. The incidence rate was stable over time (risk ratio [RR] = 1.012, P = 0.201) and lower in female patients (RR = 0.718, P < 0.001). The overall prevalence was 20.93 (95% CI, 17.97-23.86) per 100 000 persons. The average duration of PCA was calculated as 3.23 years. Approximately 70% of the patients were below the age of 45 years. Folliculitis decalvans and dissecting cellulitis were the most common subtypes of PCA. Logistic regression analysis showed that PCA was significantly associated with thyroid disorders (adjusted odds ratio = 1.64, P < 0.001). Clobetasol was the most frequently prescribed topical agent. Corticosteroids were the most common oral agents used, followed by tetracycline antibiotics. Our study is the first large-scale study reporting the epidemiology of PCA. We found a preponderance of males and neutrophil-associated subtypes of PCA, and PCA was related to thyroid disorders.

Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Age Distribution; Alopecia; Anti-Bacterial Agents; Asian People; Cellulitis; Child; Child, Preschool; Cicatrix; Clobetasol; Female; Folliculitis; Glucocorticoids; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Prevalence; Republic of Korea; Retrospective Studies; Risk Factors; Sex Distribution; Skin; Young Adult

Frontal fibrosing alopecia (FFA) is a lichen planopilaris-variant scarring alopecia that has rarely been described in men.. To characterize the clinicopathologic findings of FFA in men by studying a series of 7 male patients.. We conducted a retrospective review of all cases of male patients with FFA at the Mayo Clinic from 1992 to 2016.. Seven male patients with FFA were identified. The frontal scalp (in 6 of 7 patients), sideburns (in 4 of 7), and temporal scalp (in 4 of 7) were most frequently involved. Three patients had involvement of the eyebrows. One patient had hair loss of the upper cutaneous lip. All patients had biopsy evidence of lichen planopilaris. None of the patients had associated autoimmune or thyroid disease. Two patients had hypogonadism upon testosterone studies.. Limitations include small sample size and varied follow-up.. Although most often reported among postmenopausal women, FFA also occurs among men. The clinical and histopathologic characteristics of FFA in men parallel those described in women with FFA. Unique areas of involvement in men include sideburns and facial hair. Concomitant mucocutaneous lichen planus, autoimmune disease, and thyroid disease are infrequent among men with FFA. Distribution of hair loss and associated hormonal abnormalities aid in the recognition of FFA in men.

Topics: Adult; Aged; Alopecia; Anti-Inflammatory Agents; Cheek; Cicatrix; Clobetasol; Dermatologic Agents; Eyebrows; Forehead; Humans; Hydroxychloroquine; Lichen Planus; Male; Middle Aged; Retrospective Studies; Scalp; Tacrolimus

Lichen planopilaris (LPP) is characterized by lymphocytic infiltrate, fibrosis and potential destruction of the hair follicle. Demographic and clinical studies in LPP are limited, and racial differences have not been thoroughly investigated.. To analyse epidemiological data and clinical profiles of Chilean adults with LPP, and report on the treatments used.. This was a retrospective review of medical records and clinical follow-up of Chilean adults with a clinical and histopathological diagnosis of LPP. Treatment response was categorized clinically as none (with progression of condition), mild or satisfactory.. The study assessed 103 patients with LPP [67 women (mean age 54.1 years) and 36 men (mean age 39.1 years)]. Of the 103 patients, 41 women and 34 men were diagnosed with classic LPP (CLPP) and 26 women and 1 man with frontal fibrosing alopecia (FFA), while Graham-Little-Piccardi-Lassueur syndrome (GLPLS) was identified in 1 man. Men with CLPP had a significantly (P < 0.001) earlier age of onset than women. Scalp dysaesthesia, erythema and peripilar hyperkeratosis were common findings, and 51 (66%) of patients with CLPP had cicatricial patches, most of which were circumscribed in the vertex area. All patients with FFA had band-like scarring in the frontal and temporal hairlines. Morbidities associated with LPP were hypothyroidism, dyslipidaemia, hypertension and depression. For most patients, treatment halted or improved their inflammatory/scarring condition. A sustained combination of at least one topical (clobetasol, minoxidil and salicylic acid) and one systemic (cetirizine, hydroxychloroquine, finasteride, methotrexate and isotretinoin) medication was necessary in all of our patients with LPP.. This investigation is one of the first to describe the demographic, clinical and therapeutic features of LPP in a Latin American population. Similar profiles to previous reports may encourage research in larger multicentre international studies.

Topics: Administration, Topical; Adult; Age of Onset; Alopecia; Cetirizine; Chile; Clobetasol; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Lichen Planus; Male; Middle Aged; Retrospective Studies; Scalp Dermatoses; Sex Distribution; Sex Factors

Topics: Administration, Cutaneous; Adult; Alopecia; Clobetasol; Drug Combinations; Female; Humans; Hypertrichosis; Minoxidil; Progesterone

Topics: Alopecia; Anti-Inflammatory Agents; Antineoplastic Agents; Clobetasol; Female; Hair Follicle; Humans; Indoles; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib

Frontal fibrosing alopecia is a distinctive form of scarring alopecia presenting with frontal and temporoparietal recession of the hairline. Its etiology remains unknown, and there are no universal treatment guidelines. We conducted a retrospective cohort study to define the clinical findings and treatment outcomes of 62 patients with frontal fibrosing alopecia, one of the largest cohorts to date.. Data analysis from case notes was performed on 62 patients with a diagnosis of frontal fibrosing alopecia seen from January 2004 to March 2012.. Except for one male, all patients in this cohort were females (80% post-menopausal) and mostly Caucasians (81%). Age at onset was between 18 and 81 years. While 35% reported no symptoms, the majority (65%) had itching, pain, or burning sensations. All patients had frontal hairline recession, and 81% had complete or partial loss of eyebrows. Perifollicular erythema and perifollicular hyperkeratosis occurred in 73% and 31%, respectively. Associated autoimmune connective tissue diseases were observed in 14% of patients. Reduction in symptoms and hairline stabilization were achieved in 97% of treated patients with intralesional corticosteroids. Thirty-one percent of patients were able to stop treatments and remained in remission for six months to six years.. Frontal fibrosing alopecia is increasingly seen in postmenopausal women and rarely in men. Despite the limitations of a retrospective study, we conclude early intervention and treatment with intralesional triamcinolone acetonide may halt the progression of the disease; however, further controlled prospective studies are needed to establish treatment guidelines for frontal fibrosing alopecia.

Topics: 5-alpha Reductase Inhibitors; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azasteroids; Clobetasol; Drug Therapy, Combination; Dutasteride; Female; Fibrosis; Finasteride; Follow-Up Studies; Forehead; Humans; Male; Middle Aged; Retrospective Studies; Skin; Time Factors; Triamcinolone Acetonide; Young Adult

Topics: Administration, Cutaneous; Aged; Alopecia; Clobetasol; Eyebrows; Female; Fibrosis; Follow-Up Studies; Glucocorticoids; Humans; Treatment Outcome

Topics: Alopecia; Anti-Bacterial Agents; Anti-Inflammatory Agents; Clobetasol; Diagnosis, Differential; Doxycycline; Folliculitis; Humans; Male; Scalp Dermatoses; Treatment Outcome; Young Adult

Lichen planopilaris (LPP) and discoid lupus erythematosus (DLE) are the most common causes of lymphocytic primary cicatricial alopecia. The management of scarring alopecia can be difficult. The combination of clinical, dermoscopy and reflectance confocal microscopy (RCM), a noninvasive, high-resolution imaging technique, examinations have already been demonstrated to be useful for choosing the correct biopsy site in patients with inflammatory skin disease and obtaining microscopic diagnostic criteria.. We evaluated the usefulness in practice of RCM for the identification of criteria for LPP and DLE involving the scalp and their management during therapeutic follow-up.. Seven white patients with a previously established histological diagnosis of DLE (three) and LPP (four), were included in the study. RCM criteria for primary scarring alopecia were selected: epidermal disarray, spongiosis, exocytosis of inflammatory cells in the epidermis, interface dermatitis, peri- and intra-adnexal infiltration of inflammatory cells, dilated vessels in the dermis, dermal infiltration of inflammatory cells and melanophages and dermal sclerosis. All patients were followed up using RCM during the treatment. During follow-up the RCM evolution of the epidermal, junctional and dermal inflammation were evaluated.. A series of RCM features of scalp LPP and DLE were identified that show correlation with the histopathological evaluation. During the treatment follow-up of the cases RCM was shown to be sensitive for the identification of therapeutic response.. In our preliminary study the effective usefulness of RCM for the diagnosis of scarring alopecia and follow-up seemed to be evident. Moreover, RCM seems to be also promising for differential diagnosis between the different entities.

Topics: Aged; Alopecia; Anti-Inflammatory Agents; Clobetasol; Dermatologic Agents; Female; Humans; Hydroxychloroquine; Keratinocytes; Lichen Planus; Lupus Erythematosus, Discoid; Male; Microscopy, Confocal; Middle Aged; Observer Variation

Steven Kossard described a new type of hair loss that he named frontal postmenopausal fibrosing alopecia (PFFA). In some of his patients he observed a symmetric regression of the frontal hair line. The eyebrows of the patients were also often affected. The histology of the lesions showed lichen planopilaris. Several cases of frontal fibrosing alopecia have been described- almost all of them in elderly women. We report a women with postmenopausal frontal fibrosing alopecia of Kossard. In our patient there were no other clinical signs of lichen planus on the rest of the body After systemic and local therapy with corticosteroids we were able to observe a termination in the disease. In the subsequent 6-month control period no regrowth of the hair follicles was found. Even if there is no proof for a hormonal basis of the disease, the effectiveness of finasteride in some patients may indicate that androgens might be partially responsible of the pathogenesis of the disease. The local and systemic medication with corticosteroids are not able to bring to a permanent remission and secondary growth of the hair follicles in the affected areas and this brings to the necessity of more invasive or innovative therapeutic methods, like skin transplantation and additional application of medicaments like blockers of the 5/alpha reductase, which have proven their capacity in the androgenetic male alopecia.

Topics: Alopecia; Anti-Inflammatory Agents; Clobetasol; Female; Glucocorticoids; Hair Follicle; Humans; Methylprednisolone; Middle Aged; Postmenopause; Prednisolone; Steroids

We describe details of a very rare variant of lichen sclerosus in an elderly man. This pattern was characterized by involvement of most of the body surface by bullae, erosions and scarring, including scarring alopecia. Our patient responded to topical corticosteroids and doxycycline. Borrelia spp. have been implicated in a previous case of this variant, but we could not find any evidence of this in our patient.

Topics: Aged, 80 and over; Alopecia; Cicatrix; Clobetasol; Glucocorticoids; Humans; Lichen Sclerosus et Atrophicus; Male; Skin

Topics: Adolescent; Adult; Alopecia; Betamethasone; Child; Child, Preschool; Clobetasol; Dermatitis, Seborrheic; Female; Humans; Male; Middle Aged; Neurodermatitis; Pharmaceutical Vehicles; Pityriasis; Psoriasis; Scalp Dermatoses; Switzerland